Potential targeted therapies for cervical cancer


QIAGEN Digital Insights

Potential targeted therapies for cervical cancer

We were pleased to see this Oncotarget report includes our software CLC Genomics Workbench as an important tool in identifying and characterizing cervical cancers that are independent of Human papillomavirus (HPV).

A team at University of South Carolina’s College of Pharmacy have found evidence of a subgroup of cervical cancers with very different genetic features. Headed by Carolyn Banister, and Phillip Buckhaults, they predict that these women could potentially benefit from alternative treatments that are not usually given to cervical cancer patients. The team re-analyzed whole exome sequencing and RNA-seq data from more than 250 patients making use of read mapping, variant calling and RNA-seq analysis tools in CLC Genomics Workbench as part of their work.

We are happy that our bioinformatics tools contributed to these findings and we congratulate the University of South Carolina team on their work.